Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000950170-25-072014
Filing Date
2025-05-15
Accepted
2025-05-15 08:00:13
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 9198
  Complete submission text file 0000950170-25-072014.txt   11026
Mailing Address 40 10TH AVENUE 7TH FLOOR NEW YORK NY 10014
Business Address 40 10TH AVENUE 7TH FLOOR NEW YORK NY 10014 646-597-6980
RTW INVESTMENTS, LP (Filed by) CIK: 0001493215 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A

Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Subject) CIK: 0001806310 (see all company filings)

EIN.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-91724 | Film No.: 25948801
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)